LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Montabone, Erika"
  2. AU="Susan J. Burke"
  3. AU="Chen, Yuguang"
  4. AU="Zhao, Zhenghuan"
  5. AU="De Chiara, Anna Rosaria"
  6. AU="Savage, Anne"
  7. AU="Salamanca, Albert"
  8. AU="Zhong, Xiao-Song"
  9. AU="Deguchi, Masashi"
  10. AU="Żmuda, J"
  11. AU="Liao, Yanyan"
  12. AU="Zhu, Jin-Wei"
  13. AU="Khan, Azkia"
  14. AU="Folkman, Judah"
  15. AU=Bhatia Rajesh
  16. AU="Thobois, Stéphane"
  17. AU="Lai, Chien-Chih"
  18. AU="Ahn, Bo Young"
  19. AU="Jeje, Olamide"
  20. AU="Fine, Samson W"
  21. AU="Riemann, Burkhard"
  22. AU="Nazir, Ahsan"
  23. AU="Kawakita, Emi"
  24. AU="Wang, Junnian"
  25. AU="Nie, Chong"

Suchergebnis

Treffer 1 - 5 von insgesamt 5

Suchoptionen

  1. Artikel: Safety and Tolerability of COVID-19 Vaccine in Mast Cell Disorders Real-Life Data from a Single Centre in Italy.

    Nicola, Stefania / Mazzola, Marina / Lo Sardo, Luca / Montabone, Erika / Badiu, Iuliana / Corradi, Federica / Azzolina, Maria Carmen Rita / Dall'Acqua, Maurizio Gaspare / Rolla, Giovanni / Ridolfi, Irene / Quinternetto, Anna / Brussino, Luisa

    Vaccines

    2024  Band 12, Heft 2

    Abstract: ... ...

    Abstract Background
    Sprache Englisch
    Erscheinungsdatum 2024-02-16
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2703319-3
    ISSN 2076-393X
    ISSN 2076-393X
    DOI 10.3390/vaccines12020202
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel: A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response.

    Rossi, Daniela / Sciascia, Savino / Cecchi, Irene / Saracco, Marta / Montabone, Erika / Modena, Vittorio / Pellerito, Raffaele / Carignola, Renato / Roccatello, Dario

    Journal of clinical medicine

    2021  Band 10, Heft 2

    Abstract: Background: B-cells have been suggested to play a role in the pathogenesis of systemic sclerosis (SSc), representing, therefore, a potential therapeutic target.: Objectives: We aimed at investigating the 36-month outcomes of 20 SSc patients who ... ...

    Abstract Background: B-cells have been suggested to play a role in the pathogenesis of systemic sclerosis (SSc), representing, therefore, a potential therapeutic target.
    Objectives: We aimed at investigating the 36-month outcomes of 20 SSc patients who underwent an intensified B-depletion therapy (IBCDT) scheme, including both Rituximab (RTX) and cyclophosphamide (CYC).
    Methods: Data from 20 severe patients (18 females and 2 males, mean age 66.7 ± 11.0 years) with diffuse SSc (anti-topoisomerase I antibody in 95%) patients with multiorgan involvement including interstitial lung disease (ILD) treated with an IBCDT were prospectively collected. IBCDT comprehended: RTX 375 mg/m
    Results: After 36 months of follow-up, we recorded significant amelioration in N-terminal-pro-brain natriuretic peptide (NT-proBNP) levels (mean 385.4 ± 517 pg/mL at baseline to 279 ± 543 after 36 months). In addition, a significant radiological improvement of ILD in 20% of patients (4/20) and a radiological stabilization with no sign of progression of interstitial involvement in 13/20 (65%) were documented. A total of 3 out of 20 (15%) patients experienced a worsening of the ILD. No patient showed further decrease in functional respiratory parameters, including forced vital capacity, forced expiratory volume in one second, and mean values of diffusing capacity for carbon monoxide Moreover, no patient showed any change in the ejection fraction and pulmonary artery pressure when comparing values at baseline and after 24 and 36 months of observation. No severe infection, renal flare, RTX-related side effects were observed. No patient died.
    Conclusions: Our findings support that the IBCDT was well tolerated and might be a promising therapeutic option for the management of SSc, especially in those subjects with multiorgan involvement that includes ILD.
    Sprache Englisch
    Erscheinungsdatum 2021-01-14
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm10020292
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Vitamin D Status and Quality of Life in Systemic Sclerosis Patients.

    Montabone, Erika / Data, Valeria / Carignola, Renato

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

    2016  Band 22, Heft 4, Seite(n) 229–230

    Mesh-Begriff(e) Humans ; Quality of Life ; Scleroderma, Systemic ; Vitamin D ; Vitamins
    Chemische Substanzen Vitamins ; Vitamin D (1406-16-2)
    Sprache Englisch
    Erscheinungsdatum 2016-06
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1283266-2
    ISSN 1536-7355 ; 1076-1608
    ISSN (online) 1536-7355
    ISSN 1076-1608
    DOI 10.1097/RHU.0000000000000406
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4815: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel ; Online: Antiphospholipid Syndrome Is Still a Rare Disease-Estimated Prevalence in the Piedmont and Aosta Valley Regions of Northwest Italy: Comment on the Article by Duarte-García et al.

    Radin, Massimo / Sciascia, Savino / Bazzan, Mario / Bertero, Tiziana / Carignola, Renato / Montabone, Erika / Montaruli, Barbara / Vaccarino, Antonella / Cecchi, Irene / Rubini, Elena / Roccatello, Dario / Baldovino, Simone

    Arthritis & rheumatology (Hoboken, N.J.)

    2020  Band 72, Heft 10, Seite(n) 1774–1776

    Mesh-Begriff(e) Antiphospholipid Syndrome/epidemiology ; Humans ; Immunoglobulin G4-Related Disease ; Italy/epidemiology ; Prevalence ; Rare Diseases ; Severity of Illness Index
    Sprache Englisch
    Erscheinungsdatum 2020-09-06
    Erscheinungsland United States
    Dokumenttyp Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2756371-6
    ISSN 2326-5205 ; 2326-5191
    ISSN (online) 2326-5205
    ISSN 2326-5191
    DOI 10.1002/art.41401
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 24: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  5. Artikel ; Online: Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study.

    Negrini, Simone / Magnani, Ottavia / Matucci-Cerinic, Marco / Carignola, Renato / Data, Valeria / Montabone, Erika / Santaniello, Alessandro / Adorni, Giuditta / Murdaca, Giuseppe / Puppo, Francesco / Indiveri, Francesco / Della Rossa, Alessandra / D'Ascanio, Anna / Barsotti, Simone / Giuggioli, Dilia / Ferri, Clodoveo / Lumetti, Federica / Bosello, Silvia Laura / Canestrari, Giovanni /
    Bellando Randone, Silvia / Bruni, Cosimo / Guiducci, Serena / Battaglia, Elisabetta / De Andres, Maria Ilenia / Russo, Alessandra Azzurra / Beretta, Lorenzo

    Clinical and experimental medicine

    2019  Band 19, Heft 3, Seite(n) 357–366

    Abstract: Vasculopathy is a crucial feature of systemic sclerosis (SSc), and Raynaud's phenomenon (RP) and digital ulcers (DU) have a deep impact on the quality of patients' life. The management of vascular disease can be challenging for the clinician because of ... ...

    Abstract Vasculopathy is a crucial feature of systemic sclerosis (SSc), and Raynaud's phenomenon (RP) and digital ulcers (DU) have a deep impact on the quality of patients' life. The management of vascular disease can be challenging for the clinician because of the suboptimal tolerability of the treatments and lack of consensus on the best therapeutic approach. Intravenous iloprost, a synthetic analogue of prostacyclin, is broadly used for the treatment of RP and ischemic ulcers secondary to SSc. However, no standardized protocol on iloprost use is currently available and, consequently, the management of this treatment is largely based on the experience of each single center. The PROSIT project is an observational, multicenter study aiming to investigate the current treatments for SSc vasculopathy, the use of prostanoids, with special regard to iloprost, and the perception of the treatment from a patient's perspective. The study was conducted on a cohort of 346 patients from eight Italian centers and included a structured survey addressed to physicians, data collected from patient's medical records and two patient-administered questionnaires assessing the level of satisfaction, tolerability and perception of the efficacy of Iloprost. PROSIT data confirmed that in the contest of SSc iloprost represents the first-line choice for the management of severe RP and DU. Moreover, it is a well-tolerated treatment as reported by patients' experience. Although a standard protocol for the treatment of SSc-related vasculopathy is lacking, PROSIT study identified different therapeutic approaches largely supported by tertiary Italian centers. Further studies are needed in order to optimize the best treatment for SSc vascular diseases, in particular to improve the best iloprost schedule management.
    Mesh-Begriff(e) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Disease Management ; Female ; Humans ; Iloprost/therapeutic use ; Italy ; Male ; Middle Aged ; Peripheral Vascular Diseases/drug therapy ; Peripheral Vascular Diseases/pathology ; Retrospective Studies ; Scleroderma, Systemic/complications ; Scleroderma, Systemic/drug therapy ; Tertiary Care Centers ; Treatment Outcome ; Vasodilator Agents/therapeutic use ; Young Adult
    Chemische Substanzen Vasodilator Agents ; Iloprost (JED5K35YGL)
    Sprache Englisch
    Erscheinungsdatum 2019-04-15
    Erscheinungsland Italy
    Dokumenttyp Journal Article ; Multicenter Study ; Observational Study
    ZDB-ID 2053018-3
    ISSN 1591-9528 ; 1591-8890
    ISSN (online) 1591-9528
    ISSN 1591-8890
    DOI 10.1007/s10238-019-00553-y
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 5481: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang